Integral Health Asset Management LLC Has $49.40 Million Stock Holdings in Vera Therapeutics, Inc. $VERA

Key Points

• Integral Health Asset Management LLC boosted its stake in Vera Therapeutics by 47.8% to 1.7 million shares—worth about $49.40 million—making VERA its 5th largest holding and representing roughly 2.66% of the company.
• Wall Street consensus is a Moderate Buy (10 Buys, 1 Hold, 1 Sell) with an average price target of $81.45, while the stock trades near $39.96 and analysts' targets vary considerably.
• Insiders have sold about 33,490 shares (~$1.4 million) in the last 90 days even though institutional investors own roughly 99.21% of the stock; the company remains loss-making with analysts forecasting EPS of -2.89 for the year.

Integral Health Asset Management LLC increased its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 47.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,700,000 shares of the company's stock after acquiring an additional 550,000 shares during the quarter. Vera Therapeutics comprises 3.3% of Integral Health Asset Management LLC's holdings, making the stock its 5th largest holding. Integral Health Asset Management LLC owned about 2.66% of Vera Therapeutics worth $49,402,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the stock. Capricorn Fund Managers Ltd acquired a new stake in Vera Therapeutics during the 3rd quarter worth about $13,097,000. Swedbank AB bought a new position in shares of Vera Therapeutics in the 3rd quarter worth about $1,453,000. Squarepoint Ops LLC lifted its stake in shares of Vera Therapeutics by 232.0% in the 2nd quarter. Squarepoint Ops LLC now owns 57,519 shares of the company's stock valued at $1,355,000 after purchasing an additional 40,196 shares during the period. Bollard Group LLC bought a new stake in shares of Vera Therapeutics during the 2nd quarter valued at about $1,509,000. Finally, SG Americas Securities LLC bought a new stake in shares of Vera Therapeutics during the 3rd quarter valued at about $911,000. 99.21% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on VERA. JPMorgan Chase & Co. lowered their target price on Vera Therapeutics from $99.00 to $96.00 and set an "overweight" rating for the company in a report on Friday, December 19th. Pivotal Research set a $73.00 price target on Vera Therapeutics in a report on Friday, December 5th. Bank of America raised their price objective on shares of Vera Therapeutics from $48.00 to $66.00 and gave the stock a "buy" rating in a research report on Friday, December 19th. Wedbush lifted their price objective on shares of Vera Therapeutics from $23.00 to $33.00 and gave the company a "neutral" rating in a research note on Thursday, December 11th. Finally, Evercore boosted their target price on shares of Vera Therapeutics from $75.00 to $97.00 and gave the company an "outperform" rating in a research report on Monday, December 8th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Vera Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $81.45.

Vera Therapeutics Stock Performance

Shares of VERA stock opened at $39.96 on Friday. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.12. The firm has a fifty day simple moving average of $43.81 and a two-hundred day simple moving average of $36.75. Vera Therapeutics, Inc. has a 12 month low of $18.53 and a 12 month high of $56.05. The firm has a market capitalization of $2.80 billion, a PE ratio of -8.58 and a beta of 1.17.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.05). During the same quarter in the previous year, the company earned ($0.72) EPS. Analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Insider Buying and Selling

In other Vera Therapeutics news, insider Laurence Matthew Skelton sold 1,582 shares of the business's stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $66,412.36. Following the completion of the sale, the insider directly owned 64,218 shares of the company's stock, valued at approximately $2,695,871.64. The trade was a 2.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider William D. Turner sold 2,187 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $91,810.26. Following the completion of the sale, the insider directly owned 45,313 shares of the company's stock, valued at approximately $1,902,239.74. This trade represents a 4.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 33,490 shares of company stock worth $1,405,910 over the last ninety days. Insiders own 16.30% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.